Rare but Targetable: EGFR Mutations Identified in 0.08% of Ovarian Cancers
EGFR mutations found in 0.08% of ovarian cancers; one patient achieved 17+ month response to osimertinib.
Ovarian Cancer
Latest Post
Anixa FSHR CAR-T Demonstrates Safety at 30-Fold Dose Increase in Ovarian Cancer Phase 1 Trial
Fourth cohort receiving 30x initial dose with no dose-limiting toxicities observed to date.
